Comparison of monoclonal antibodies targeting CD38, SLAMF7 and PD-1/PD-L1 in combination with Bortezomib/Immunomodulators plus dexamethasone/prednisone for the treatment of multiple myeloma: an indirect-comparison Meta-analysis of randomised controlled trials

Wu, Ye; Wu, Xia; Liu, Xiaoyan; Zheng, Xue; Deng, Juelin; Gong, Yuping

doi:10.1186/s12885-021-08588-9

Cited by 3 publications

(2 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multiple myeloma (MM) is a genetically heterogeneous clonal plasma cell disorder, which is the second most common malignancy in the hematological system ( 191 , 192 ). The immune dysfunction is critical for the genesis of MM.…”

Section: Pd-1/pd-l1 and Inhibitors In Human Hematological Malignanciesmentioning

confidence: 99%

The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers

et al. 2022

View full text Add to dashboard Cite

Programmed cell death protein-1 (PD-1) is a checkpoint receptor expressed on the surface of various immune cells. PD-L1, the natural receptor for PD-1, is mainly expressed in tumor cells. Studies have indicated that PD-1 and PD-L1 are closely associated with the progression of human cancers and are promising biomarkers for cancer therapy. Moreover, the interaction of PD-1 and PD-L1 is one of the important mechanism by which human tumors generate immune escape. This article provides a review on the role of PD-L1/PD-1, mechanisms of immune response and resistance, as well as immune-related adverse events in the treatment of anti-PD-1/PD-L1 immunotherapy in human cancers. Moreover, we summarized a large number of clinical trials to successfully reveal that PD-1/PD-L1 Immune-checkpoint inhibitors have manifested promising therapeutic effects, which have been evaluated from different perspectives, including overall survival, objective effective rate and medium progression-free survival. Finally, we pointed out the current problems faced by PD-1/PD-L1 Immune-checkpoint inhibitors and its future prospects. Although PD-1/PD-L1 immune checkpoint inhibitors have been widely used in the treatment of human cancers, tough challenges still remain. Combination therapy and predictive models based on integrated biomarker determination theory may be the future directions for the application of PD-1/PD-L1 Immune-checkpoint inhibitors in treating human cancers.

show abstract

Section: Pd-1/pd-l1 and Inhibitors In Human Hematological Malignanciesmentioning

confidence: 99%

The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers

et al. 2022

View full text Add to dashboard Cite

show abstract

“…During the past 2 decades, agents with novel mechanisms of action, such as monoclonal antibodies (MAbs) and histone deacetylase inhibitors (HDACs), have been applied to treat RR-MM [50]. Many clinical trials have assessed the effect and safety of MAbs in combination with proteasome inhibitors (PIs) or immunomodulatory agents (IMiDs) plus dexamethasone/prednisone for the treatment of MM [51]. The choice of therapy for RR-MM requires careful consideration of patient factors including age, frailty, comorbidities, and disease factors, such as symptom burden or biology, as well as treatment-related factors, including drug toxicities and responses to previous therapies.…”

Section: Treatment Of Relapsed and Refractory MMmentioning

confidence: 99%

Multiple Myeloma in the Era of Novel Agents and Stem Cell Therapies

Al-Anazi¹

2023

Recent Updates on Multiple Myeloma

View full text Add to dashboard Cite

The recent availability of several lines of novel therapeutic agents such as immunomodulatory agents, proteasome inhibitors, and monoclonal antibodies; the widespread utilization of hematopoietic stem cell transplantation; the use of advanced diagnostic techniques that allow risk stratification and monitoring of treatment responses; and the general improvement in health care have revolutionized treatment of patients with multiple myeloma and this has translated into significant improvements in survival outcomes. Monitoring of minimal residual disease can guide the intensity of treatment, and the efficient application of modern diagnostic tools in monitoring treatment responses in real-world clinical practice can hopefully be achieved in the near future. The recent use of quadruplet regimens in the treatment of patients with multiple myeloma has translated into unprecedented treatment responses and survival outcomes. Also, chimeric antigen receptor T-cell therapy and bispecific antibodies represent a new dimension in the precision medicine in MM. Additionally, our ability to induce deep responses has improved, and the treatment goal in myeloma patients tolerating the recommended therapy has moved from delay of disease progression to induction of the deepest possible response.

show abstract

Anti-Multiple Myeloma Potential of Secondary Metabolites from Hibiscus sabdariffa—Part 2

et al. 2021

View full text Add to dashboard Cite

Multiple Myeloma (MM) is an aggressive tumor causing millions of deaths every year and currently available therapies are often unsuccessful or correlated with severe side effects. In our previous work we demonstrated that the Hibiscus sabdariffa hydroalcoholic extract inhibits the growth of the MM cell line and we isolated two metabolites responsible for the activity: Hib-ester and Hib-carbaldehyde. Herein we report their interaction with proteasome, one of the main targets in the fight against MM. The molecular modelling study outlined a good interaction of both compounds with the target and these results prompted us to investigate their potential to inhibit proteasome. Metabolites were then isolated from the calyces and an extract with a high content of Hib-ester and Hib-carbaldehyde was prepared. An anticancer profile was drawn, evaluating apoptosis, autophagy and proteasome inhibition, with the anticancer properties being mainly attributed to the Hib-ester and Hib-carbaldehyde, while the proteasome inhibition of the extract could also be ascribed to the presence of anthocyanins, a class of secondary metabolites already known for their proteasome inhibitory activity.

show abstract

Comparison of monoclonal antibodies targeting CD38, SLAMF7 and PD-1/PD-L1 in combination with Bortezomib/Immunomodulators plus dexamethasone/prednisone for the treatment of multiple myeloma: an indirect-comparison Meta-analysis of randomised controlled trials

Cited by 3 publications

References 37 publications

The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers

The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers

Multiple Myeloma in the Era of Novel Agents and Stem Cell Therapies

Anti-Multiple Myeloma Potential of Secondary Metabolites from Hibiscus sabdariffa—Part 2

Contact Info

Product

Resources

About